CE Disclosures and Faculty Information

• OVERVIEW OF ACTIVITY

  Colorectal cancer is one of the most rapidly evolving fields in oncology nursing. Published results from ongoing clinical trials lead to the continuous emergence of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care, oncology nurses must be well informed of these advances, including the relative efficacy of new agents and regimens and strategies to minimize and manage associated toxicities. This program provides nurses with access to the latest research developments and opinions of oncology healthcare professionals with experience and expertise in the field, in addition to perspectives of patients undergoing treatment.

  PURPOSE STATEMENT

  To present the most current research developments in colorectal cancer and to provide the perspectives of medical oncologists, oncology nurses and patients on the diagnosis and treatment of colorectal cancer.

  EDUCATIONAL OBJECTIVES FOR THIS ISSUE OF COLORECTAL CANCER UPDATE FOR NURSES

  • Communicate the risks and benefits of adjuvant systemic therapy to patients with Stage II and III colon cancer.
  • Develop an evidence-based algorithm for the prevention and amelioration of side effects associated with oxaliplatin-based chemotherapy.
  • Describe the clinical impact of and toxicities associated with the use of bevacizumab for metastatic colon cancer.
  • Recall the rationale for surgical resection as part of the multidisciplinary management of colorectal cancer with isolated hepatic metastases.
  • Discuss the role of the oncology clinician in the care of patients who choose alternative treatments to complement conventional therapy.
  • Recognize the psychosocial and emotional needs of patients, caregivers and their loved ones facing the diagnosis and treatment of colon cancer.

  ACCREDITATION STATEMENTS

  Research To Practice is an approved provider of continuing nursing education by NJSNA, an accredited approver, by the American Nurses Credentialing Center’s Commission on Accreditation.
  
  This activity for 1.7 contact hours is provided by Research To Practice. Provider Number: P215-01/07-10.
  
  HOW TO USE THIS CNE ACTIVITY
  
  CME credit is no longer available for this issue
  

  This is an audio CNE program. This website contains CNE information, including learning objectives, faculty disclosures, a Post-test and an Educational Assessment and Credit Form, as well as links to relevant abstracts and full-text articles.

  CONTENT VALIDATION AND DISCLOSURES

  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

  FACULTY — Mr Weber had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Venook — Advisory Committee: Amgen Inc, ImClone Systems Incorporated; Grant Funding: Genentech BioOncology; Paid Research: Bayer Pharmaceuticals Corporation, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Pfizer Inc.

  EDITOR — Neil Love: Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: Abraxis BioScience, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, Eli Lilly and Company, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, ImClone Systems Incorporated, Merck and Company Inc, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Ortho Biotech Products LP, OSI Oncology, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis, Synta Pharmaceuticals Corp and Wyeth.

  RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

  ---

  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

  This program is supported by educational grants from Genentech BioOncology and Sanofi-Aventis.

  Hardware/Software Requirements:
  An Internet connection that is at least 28.8 Kbps
  A monitor set to 1280 x 1024 pixels or more
  Netscape 7.x or newer, Internet Explorer 5.x or newer, or Firefox
  Macromedia Flash plug-in 6.0 or greater
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio

  Last review date: February 2009
  Expiration date: February 2010